McLean, Robert R.
Sima, Adam P.
Beaty, Silky
Jones, Eric A.
Eckmann, Thomas
Low, Robert
McClung, Laura
Spitzer, Rebecca L.
Stark, Jeffrey
Armstrong, April
Clinical trials referenced in this document:
Documents that mention this clinical trial
Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry
https://doi.org/10.1007/s13555-023-01028-5
Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry
https://doi.org/10.1007/s13555-023-01027-6
Funding for this research was provided by:
CorEvitas, LLC
UCB Pharma
Article History
Received: 30 June 2023
Accepted: 6 September 2023
First Online: 27 September 2023
Declarations
:
: Robert R. McLean, Adam P. Sima, Eric A. Jones, Thomas Eckmann, Rebecca L. Spitzer: Employees of CorEvitas; Silky Beaty, Robert Low, Laura McClung, Jeffrey Stark: Employees and shareholders of UCB Pharma; April Armstrong: Has served as a research investigator and/or scientific advisor to AbbVie, Almirall, Arcutis, ASLAN, Boehringer Ingelheim, BMS, Dermavant, Dermira, Eli Lilly, EPI, Incyte, Janssen, LEO Pharma, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sun Pharma, Sanofi, and UCB Pharma; CorEvitas, LLC, has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Arena, Boehringer Ingelheim, BMS, Celgene, Chugai, Eli Lilly, Genentech, Gilead, GSK, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB Pharma. The CorEvitas Psoriasis Registry was developed in collaboration with the National Psoriasis Foundation.
: This study was performed following the guidelines for Good Pharmacoepidemiology Practice [CitationRef removed] and in accordance with the current version of the applicable regulatory and International Council for Harmonisation Good Clinical Practice requirements [CitationRef removed], the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved. All patients provided written informed consent for participation in the registry. All participating investigators were required to obtain full board approval for conducting non-interventional research involving human subjects with a limited dataset. Sponsor (CorEvitas, LLC) approval and continuing review was obtained through a central IRB (IntegReview, protocol number is Corrona-PSO-500). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC, prior to the initiation of any study procedures.